3rd Quarter - Report — CEPHEID for CEPHEID (2016)

Firm

CEPHEID

Client

CEPHEID

Income

—

Expenses

$37,546

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Science/Technology SCI

molecular diagnostic tests, infection control platforms, regulation of laboratory tests, reimbursement for laboratory tests. antimicrobial resistance/antibiotic stewardship

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: Health & Human Services, Dept of (HHS); White House Office; Veterans Affairs, Dept of (VA); SENATE; Centers For Medicare and Medicaid Services (CMS); Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC)

Health Issues HCR

Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance, antimicrobial resistance/antibiotic stewardship), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight of clinical laboratory tests, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues, disease specific issues (multi-drug resistant tuberculosis, infection)

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: White House Office; Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Agency for Healthcare Research & Quality (AHRQ); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA); Veterans Affairs, Dept of (VA)

Medicare/Medicaid MMM

Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: Health & Human Services, Dept of (HHS); White House Office; Food & Drug Administration (FDA); Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); SENATE; Centers For Medicare and Medicaid Services (CMS); Veterans Affairs, Dept of (VA)

Medical/Disease Research/Clinical Labs MED

Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: Centers For Disease Control & Prevention (CDC); Veterans Affairs, Dept of (VA); Food & Drug Administration (FDA); White House Office; Health & Human Services, Dept of (HHS); SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Agency for Healthcare Research & Quality (AHRQ)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.